/Modified Immune Cells Having Adenosine Deaminase Base Editors For Modifying A Nucleobase In A Target Sequence
Abstract
The present invention features genetically modified immune cells comprising novel adenosine base editors (e.g., ABE8) having enhanced anti-neoplasia activity, resistance to immune suppression, and decreased risk of eliciting a graft-versus-host reaction or host-versus-graft reaction, or a combination thereof. The present invention also features methods for producing and using these modified immune effector cells.
Full Text
What is claimed is:
The present invention features genetically modified immune cells comprising novel adenosine base editors (e.g., ABE8) having enhanced anti-neoplasia activity, resistance to immune suppression, and decreased risk of eliciting a graft-versus-host reaction or host-versus-graft reaction, or a combination thereof. The present invention also features methods for producing and using these modified immune effector cells.
Timeline
Filed
02/27/2026Published
06/25/2026Granted
Not AvailableIPC Codes(3)
C12N 15/113:Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12N 9/22:Ribonucleases
C12N 9/78:acting on carbon to nitrogen bonds other than peptide bonds (3.5)